Micromedic Obtains EU CE Mark for CellDetect® Test for Detecting Recurrence of Bladder Cancer
Micromedic Technologies Inc. announced that its CellDetect® non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and countries that adopted the European regulatory standards under the CE Mark.
The CE marking recognizes the conformity of the CellDetect® non-invasive test for detecting recurrence of bladder cancer in urine with the relevant directive of the European Community.
Micromedic also announced that the European Patent Office has issued a patent related to the core of the CellDetect® technology. The patent will be in effect until March 2027.